Immedica to present new pegzilarginase data at the SSIEM Annual Symposium 2023
Stockholm, August 28, 2023 Immedica today announces the presentation of new data at the SSIEM (Society for the Study of Inborn Errors of Metabolism) annual symposium taking place in Jerusalem, Israel. The presentation highlights important long-term patient-level data on pegzilarginase, a potential first disease modifying treatment for arginase 1 deficiency (ARG1-D). Anders Edvell, Immedica CEO commented: “We are very pleased to be able to present this new patient-level data that demonstrates long-term clinical outcomes of pegzilarginase for the treatment of ARG1-D, a disease where the